Search
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]
Mixtures: LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL), LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL)Categories: Alimentary Tract and Metabolism, Amino Acids, Peptides, and ProteinsAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAtopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.
Products: CIBINQO® 100MG, Cibinqo 100mg Film-Coated TabletsPhenylbutazone
go.drugbank.com/drugs/DB00812ApprovedVet approvedWithdrawnIt also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). … A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis.
Synonyms: 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine, 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedioneCategories: Antiinflammatory and Antirheumatic Products, Non-Steroids, phenylbutazone and corticosteroidsCoenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
Mixtures: IFEX and MESNEX, IFEX and MESNEXCategories: Cough and Cold PreparationsDesoximetasone
go.drugbank.com/drugs/DB00547ApprovedA topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Categories: Hormones, Hormone Substitutes, and Hormone AntagonistsProducts: Topicort Crm 2.5mg/gm, Topicort Ointment 2.5mg/gmGlycine
go.drugbank.com/drugs/DB00145ApprovedInvestigationalNutraceuticalVet approvedA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
Mixtures: Aminosyn II and Dextrose, Aminosyn II and DextroseCategories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsCefixime
go.drugbank.com/drugs/DB00671ApprovedInvestigational[L49293] The beta-lactam ring of cefixime inhibits bacterial cell wall synthesis by binding to the penicillin-binding proteins which will then result in lysis. … bacteria, and meningitis.
International brands: Omnatax-OCategories: cefixime and ornidazole, cefixime and azithromycinBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigationalBy inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.
Categories: Antineoplastic and Immunomodulating AgentsProducts: OLUMIANT FILM-COATED TABLET 2MG, Olumiant 2mg Film-Coated TabletsDesloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalDesloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system. … Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action.
Mixtures: Aerius D-12 Modified Release Tablets 2.5mg/120mg, NEUMOLEX® NFCategories: Loratadine and derivatives, Histamine H1 Antagonists, Non-SedatingEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
Categories: Amino Acids, Peptides, and Proteins, Blood and Blood Forming OrgansProducts: HEMLIBRA 150MG/ML SOLUTION FOR INJECTION, HEMLIBRA SOLUTION FOR INJECTION 150MG/ML